| Metric | Value (₹ Cr) | vs Q1 FY27 |
|---|---|---|
| Revenue | 105.61 | 20.6% |
| Total Income | 105.66 | 20.6% |
| Expenditure | 82.18 | 11.1% |
| PBT | 23.47 | 71.8% |
| Net Profit | 17.18 | 107.4% |
| OPM | 23.90% | 6.09pp |
| NPM | 16.26% | 6.81pp |
| EPS | 0.32 | 100.0% |
Strong revenue growth masks margin miss; execution risk elevated
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 7/10
Grade B
Revenue guidance on track (H1 ₹193 Cr vs. target ₹380-400 Cr annual). Margin guidance being missed by ~150 bps (23.9% actual vs. 25-30%).
Optimistic
next 1–2 quarters
Optimistic
multi-year
Strong revenue growth (102% YoY) and FY27 guidance tracking well (H1 ₹193 Cr toward ₹380-400 Cr target), but delivered Q2 margin of 23.9% fell short of 25-30% guidance due to raw material pricing and geopolitical pressure. FY28 growth target of ₹650-700 Cr is backed by concrete 1,200 MT expansion, but multiple new revenue streams (CDMO delayed to Q4, Medicos to Q3) remain unproven.
₹105.6 Cr
Revenue · +102.3% YoY₹17.2 Cr
Reported PAT · +84.4% YoYCompressing
Margins · vs guidance: MixedDid the claims hold up?
Revenue growth 102.3% YoY, ₹105.61 Cr vs ₹52.2 Cr
METDelivered ₹105.6 Cr vs prior ₹52.2 Cr = 102.3% growth
PAT growth 84.4% YoY, ₹17.18 Cr vs ₹9.32 Cr
METDelivered ₹17.2 Cr vs prior ₹9.32 Cr = 84.4% growth
EBITDA margin recovery to 25%-30% range by Q3-Q4
OVERSTATEDQ2 actual margin 23.9% (EBITDA ₹25.24 Cr). Management acknowledges miss, blames raw material pricing pressure and geopolitical situation.
FY27 guidance ₹380-400 Cr on track
METH1 revenue ₹193.17 Cr (vs ₹85.5 Cr prior). At run-rate, tracking toward ₹380 Cr minimum.
Consolidated capacity 1,900-2,000 MT vs 400 MT prior
METManagement states 1,900-2,000 MT consolidated (Anlon stand-alone at 85-86% utilization, consolidated at 65-67%).
Earnings quality
What changed since the last call
Margin guidance maintained but at risk
DowngradePrior call (Q1): 'stabilizing margin 25%-30%'. Q2 actual: 23.9%. Management says 'temporary' due to geopolitics, aiming for 25%-27% by year-end, but near-term pressure evident.
CDMO timeline pushed back
DowngradeManagement said 'expecting first revenue Q3 FY27'; now confirmed delayed to Q4. Molecule 1 validation complete but commercialization depends on customer ramp-up (not counted in FY28 projections).
Capital raise delayed
Downgrade₹65-70 Cr equity raise for capex received approval in November. Funding needed for ₹130 Cr capex (₹70 Cr debt-funded). Timing risk could impact expansion pace.
FY28 guidance upgraded to ₹650-700 Cr
UpgradeNew forward guidance on Q2 call. Prior guidance was FY27 ₹350-400 Cr. FY28 adds 1,200 MT capacity by Q1, implies 67-80% growth.
The Q&A
Analysts pressed hard on margin miss (Vaibhav Mishra: 'can we expect margins above 24%?'), CDMO timeline (Rounak Baipai: 'when will first molecule commercialize?'), and acquisition impact (Bhavesh Patel: 'PAT margin decreasing, when steady-state?'). Management held up reasonably well, providing specific timelines (Q1 FY28 for expansion, Q4 for CDMO first revenue) and blaming external factors (raw material pricing) rather than operational issues. Some hedging on CDMO value-add ('too early to commit') and dividend ('will see cash flow first'). Overall, transparent but defensive tone.
FY27-FY28 revenue guidance — Nishita, Sapphire Capital
AnsweredFY27 ₹380-400 Cr, almost in line with prior target. On track. FY28 ₹650-700 Cr (excluding CDMO).
Margin sustainability — Vaibhav Mishra, Finvestors Research
PartialSituation improved from Q1. Achieved 23.9% in Q2. Hoping for 25%-26% by year-end as price revisions take effect. 23%-24% floor from raw material pressure; hope to reach 25%-27% sustainable.
Capacity expansion timeline — Vaibhav Mishra, Finvestors Research
AnsweredConstruction started. Finish first floor by end-November. Full commissioning by Q1 FY28. Possible 1-2 month delay if regulatory hurdles arise.
CDMO revenue timeline — Vaibhav Mishra, Finvestors Research
AnsweredDelayed 1-2 months past Q3. Expected end-Q3 or early-Q4. Depends on customer ramp-up; not yet included in FY28 revenue projections.
Margin profile by segment — Rounak Baipai, Wealthtime Advisory
AnsweredAPI ~35% gross EBITDA margin. Intermediate ~35%. Consolidated 65-67% utilization; Anlon stand-alone 85-86%.
CDMO commercialization and value-add — Rounak Baipai, Wealthtime Advisory
PartialMolecule 1 commercial supply delayed to Q3-Q4. Molecules 2-3 validation by Q1 FY28. Too early to commit value to FY28 guidance. 1-3 years to market acceptability. Right now, focused on existing business.
Acquisition integration and EBITDA margin — Bhavesh Patel, Patel Investments
PartialApiqo is lower margin (20%-23% EBITDA) vs. pharma. Acquisition just 6, 8 months old. By FY27 you'll see improvement in ROE. FY28 profitability will improve from CDMO and new products. Sustainability: 25%-27% EBITDA, 11%-14% PAT (or 11%-13% consolidated impact).
DMF filing progress — Prateek Srivastava, Nivesh Vista
Answered7 DMF planned in FY27. 3 almost done by Dec, another 2-3 by Q4. Ketoprofen US filing on hold pending customer (FDA trigger not yet started). ~6 DMF filed definitely by FY27, maybe 1-2 delayed.
Capital raise and debt — Deepak Chokhani, Raid Capital
Answered₹65-70 Cr planned for capex and acquisitions. Approval received in November. Allotment and call within next 8-10 days. Total capex ₹130 Cr (₹70 Cr debt-funded).
Dividend and cash flow outlook — Bhavesh Patel, Patel Investments
PartialEarly to commit on dividend. Management will see cash flow first. H1 FY27 operating cash flow ₹7.94 Cr vs ₹79.44 Cr prior year (WC improved). Aiming for cash flow positive by end-FY27.
Medical device (Anlon Medicos) ramp and revenue — Priyansh Miri, NGP Family Office
PartialRevenue starts Q3 FY27 (not material). FY28 ₹650-700 Cr base guidance excludes medical devices. Ointment topical gel expected Q1 FY28 DCGI approval; full pan-India launch. Revenue potential ₹70-80 Cr surgical devices business, ₹70-80 Cr ointment at peak.
Loxoprofen (Anlon Medicos) expansion — Priyansh Miri, NGP Family Office
AnsweredLoxoprofen topical gel: CDSCO and DCGI approval expected FY28 (earliest Q1 FY28). Pan-India marketing. Existing tablet/capsule ₹80-90 Cr; ointment 2x-3x higher. Not included in FY28 ₹650-700 Cr guidance yet.
China Plus One strategy and moat — Priyansh Miri, NGP Family Office
AnsweredNo China dependency in our Ketoprofen, Desketoprofen, Loxoprofen portfolio. We're replacing Chinese manufacturers globally. Cost at par or 10%+ cheaper than China. Registration is moat, not price.
Guidance
FY27 ₹380-400 Cr (reiterated)
HighH1 delivered ₹193.17 Cr; tracking well. Prior guidance from Q1 call maintained.
FY28 ₹650-700 Cr (new)
MediumBase business guided; excludes CDMO first revenue and medical device ramp (expected Q3 start). Backed by 1,200 MT expansion by Q1 FY28.
EBITDA 25%-30% (maintained from Q1 call)
LowQ2 actual 23.9%. Management targets 25%-27% recovery by year-end FY27; cites raw material normalization.
PAT margin 13%-14% core; 11%-13% consolidated
MediumApiqo acquisition at lower margin (20%-23% EBITDA). Consolidation drag evident; improvement expected as mix shifts toward higher-margin new products.
₹130 Cr capex FY27-FY28 (₹70 Cr debt, ₹65-70 Cr equity)
MediumEquity raise approval received November 2026. Debt funding to support Rajkot expansion (1,200 MT) and Apiqo capex.
Risks the call surfaced
Margin compression
HighQ2 margin 23.9% vs. 25%-30% guidance. Raw material (crude, petrochemical solvents) pricing post-geopolitical spike. Apiqo at 20%-23% margin (lower than Anlon core).
New product timing risk
HighCDMO first molecule delayed to Q4 (from Q3 guidance). Anlon Medicos surgical implants to start Q3 but minimal FY27 revenue. Loxoprofen ointment DCGI approval awaited (Q1 FY28 expected).
Integration execution risk
MediumApiqo (43.7% of H1 revenue) and Biozotic (11.7%) acquired early FY27; lower margin profile (20%-23% EBITDA vs. core 25%-27%). Consolidation drag evident in PAT margin.
Regulatory approval risk
Medium7 DMF filings planned in FY27 (3 done by Q2, 6 by year-end targeted). Ketoprofen US filing on hold pending customer FDA trigger. Loxoprofen ointment DCGI approval expected Q1 FY28 but on hold for complexity and stability data.
Capacity expansion execution
MediumConstruction underway; finish first floor by end-November. Full commissioning targeted Q1 FY28 but at risk from regulatory/statutory approvals (mentioned 1-2 month possible delay).
Working capital cycle
LowReceivables annualized 123 days (improved but still elevated). Payables 40 days. Management targeting 170-180 day optimal working capital cycle. Current position strains cash availability.
Management
Score 7/10. Clear and detailed on financial metrics and timelines. Transparent on margin miss (blames external factors, not opex). Candid on regulatory delays and project timelines. Some hedging on CDMO value-add and dividend. Revenue track record strong (102% YoY growth, H1 ₹193 Cr on guidance track). Margin guidance missed (23.9% vs. 25%-30%); management acknowledges and explains but recovery credibility tested. Acquisitions integrated (6-8 months old) but still drag on profitability.
1 · Q3 FY27 (Nov-Dec 2026)
Anlon Medicos revenue first contribution from surgical implants; DMF filings 3-4 more planned
2 · Q4 FY27 (Jan-Mar 2027)
CDMO first molecule commercial supply to start; Loxoprofen topical DCGI approval expected
3 · Q1 FY28 (Apr-Jun 2027)
Rajkot capacity expansion (1,200 MT, 8 new clean lines) commissioned; Anlon Biologies first revenue
FY28 growth target of ₹650-700 Cr is backed by concrete 1,200 MT expansion, but multiple new revenue streams (CDMO delayed to Q4, Medicos to Q3) remain unproven.
Revenue Flying, Margins Grounded—Can Anlon Restore Both?
Q2 delivered 102% revenue growth and is tracking to full-year guidance, but EBITDA margin came in at 23.9% versus the promised 25–30%. That's not a one-time miss—it's an operational test of management's execution credibility going into FY28.
₹105.6 Cr
+102% YoY
23.9%
vs 25–30% guidance
₹17.2 Cr
+84% YoY
₹193.17 Cr
on pace for ₹380–400 Cr FY27
The headline reads textbook: double-digit revenue growth, PAT up 84%. But there's a wedge between the result and the guidance. EBITDA margin landed at 23.9%—a 110 basis point miss against the promised 25–30% range. That's not a rounding error or a segment mix shift. It's an operational shortfall, and while management's explanation—raw material pricing in a geopolitical crunch—is credible, it's not bulletproof. The question now is whether the recovery to 25–27% by year-end actually happens, or whether this marks a structural shift in Anlon's profitability profile.
Where the margin miss sits
Raw material pricing pressure is real. The earnings call confirms Anlon cited geopolitical disruption driving crude and solvents pricing. This is an external headwind, not an operational slip. But it's also a risk that persists. Price revisions to customers are underway—management expects to see the benefit by Q3–Q4—but the company won't control the pace of raw material normalization.
Acquisition drag is structural, not temporary. Apiqo Organics (43.7% of H1 revenue) and Biozotic (11.7%) are integrating at lower margins than the Anlon Healthcare core. This was disclosed at acquisition time, but Q2 marks the first time we see it hit consolidated numbers. The drag is real; recovery depends on operational improvements and product mix shifts at those businesses, not just external price normalization.
Revenue growth 102% YoY, ₹105.61 Cr
₹105.6 Cr vs prior ₹52.2 Cr
102.3% growth
Supported
PAT growth 84.4% YoY, ₹17.18 Cr
₹17.2 Cr vs prior ₹9.32 Cr
84.4% growth
Supported
EBITDA margin 25–30% recovery target
Q2 actual 23.9% vs 25–30% range
110 bps miss; management targeting 25–27% by year-end
Overstated
FY27 guidance ₹380–400 Cr on track
H1 ₹193.17 Cr
At midpoint run-rate, tracking minimum ₹380 Cr
Supported
Consolidated capacity 1,900–2,000 MT, 65–67% utilization
Anlon stand-alone 85–86%, acquired businesses 60–65%
Management states consolidated at 65–67%
Supported
FY28 ₹650–700 Cr growth backed by 1,200 MT expansion Q1 FY28
67–80% growth from current quarterly run-rate
Rajkot greenfield under construction; first floor completion targeted end-Nov
Supported but execution-dependent
What changed on this call
FY28 revenue guidance raised to ₹650–700 Cr (new). Prior guidance was FY27 only. This implies 67–80% growth from current quarterly run-rate—aggressive but grounded in concrete capacity (1,200 MT expansion commissioning Q1 FY28). Explicitly excludes CDMO first revenue and medical device ramp-up, de-risking the projection.
CDMO commercial supply timeline slipped by 1–2 months. From "Q3 FY27" to "end-Q3 or early-Q4." First molecule validation is complete, but customer ramp-up timing is now the binding constraint. This is a minor slip, but it signals execution risk in new revenue streams when management promised visibility.
Capital raise formalized and fast-tracked. ₹65–70 Cr equity raise approval received in November; allotment expected within 8–10 days. Funds allocated to capex (₹130 Cr total, ₹70 Cr debt-funded) and acquisitions. This de-risks the Rajkot expansion funding but ties execution to equity dilution and integration burn.
Margin guidance maintained but now at risk. Prior call (Q1): management was confident in 25–30% stabilization. Q2 actual: 23.9%. Management now targeting 25–27% (narrower range, lower floor) by year-end. This is a silent downgrade—the confidence envelope has tightened, and management has retreated from the upper bound.
The bull-bear ledger
Revenue growth is real and strong (102% YoY, ₹105.6 Cr). Not a one-quarter pop.
H1 tracking to full-year FY27 guidance (₹193 Cr toward ₹380–400 Cr). Guidance discipline intact.
FY28 growth target (₹650–700 Cr) backed by concrete 1,200 MT capacity expansion, not vaporware.
Positioned in China Plus One narrative: cost ~10% below Chinese suppliers, regulatory moat (DMF approvals, registrations).
International regulatory progress (PMDA Japan, NMPA China, EDQM Europe approvals for Loxoprofen variants).
EBITDA margin 23.9% vs 25–30% guidance is a 110 bps operational miss, not excused by one-time items.
Acquisitions (Apiqo 43.7% of revenue, Biozotic 11.7%) integrating at 20–23% EBITDA margin vs. core 25–27%. Consolidated drag is structural.
New revenue streams (CDMO, Medicos, Loxoprofen ointment) delayed or minimal in FY27; FY28 uplift depends on execution.
Operating cash flow H1 ₹7.94 Cr (vs ₹79.44 Cr prior). Working capital cycle stressed; receivables at 123 days, payables 40 days.
Raw material pricing (crude, solvents) normalization uncertain; geopolitical pressure may persist.
Risks ranked by how much they should concern a holder
Margin compression vs guidance (23.9% actual vs 25–30% target)
HighEBITDA margin miss is 110 bps and directly impacts profitability. If not recovered by year-end, it signals a structural shift in cost structure or pricing power. Acquisition drag (Apiqo 20–23% vs core 25–27%) persists; external raw material normalization may not deliver expected relief.
New revenue streams (CDMO, Medicos, Loxoprofen ointment) delayed or unproven
HighFY28 ₹650–700 Cr guidance explicitly excludes these pending clarity. If delayed further or underperform, growth target misses. CDMO first commercial supply pushed Q3→Q4; Medicos minimal FY27 revenue; Loxoprofen DCGI approval timing uncertain.
Acquisition integration drag (Apiqo, Biozotic) on consolidated profitability
MediumApiqo (43.7% of H1 revenue) and Biozotic (11.7%) integrate at 20–23% EBITDA margin. ROE dilution evident; management says improvement by FY28 but no proof yet. If integration stalls, consolidated margin stays depressed.
Capacity expansion execution (Rajkot 1,200 MT, Q1 FY28 commissioning)
MediumCore to FY28 growth story. Under construction, first floor on track, but regulatory approval risk mentioned (1–2 month possible delay). Any delay pushes new capacity revenue into FY28 H2+, testing growth targets.
Regulatory approval delays (7 DMF filings, Loxoprofen ointment DCGI, Ketoprofen US)
MediumDMF filing progress on track (3 of 7 done, 6 by year-end targeted), but Ketoprofen US on hold, Loxoprofen DCGI timing vague. Delays push commercialization into FY28+.
Raw material pricing persistence (crude, petrochemical solvents)
MediumGeopolitical situation cited; normalization uncertain. Q2 margin miss attributed to this; if pricing doesn't normalize, even FY28 margin recovery target (25–27%) at risk.
Working capital cycle stress (123-day receivables, 40-day payables)
LowManagement improving but cycle still elevated versus 170–180 day target. Strains cash availability for capex and growth investments. Addressable through credit control and supplier terms.
How the street is positioned
The stock sits at ₹27.99, down 83.8% from its all-time high of ₹172.75, but trading above its SMA20 (₹26.53), SMA50 (₹24.25), and SMA200 (₹20.41). This tells two stories: the drawdown was sharp and deep, but recovery momentum is real. RSI at 57.3 (neutral) suggests no extreme overbought or oversold condition.
FII ownership rose to 1.67% in Q1 FY27 (from 0.32% in Q4 FY26), a 135 basis point jump. This signals recent institutional entry, though absolute position remains modest. DII trimmed from 4.60% to 1.22%—a significant pullback. Promoter stake unchanged at 52.68%, showing no insider selling signal.
Bulk block activity over the last 6 months shows Neo Apex engaging in both buys and sells across a ₹26–36 range—a pattern suggesting tactical trading rather than conviction. No promoter-linked selling near the highs. The depth of institutional positioning is still building.
The disconnect is instructive: the stock has recovered 170% off its low but lost 84% from its high. Q2's 102% revenue growth and strong H1 track record should spark a positive catalyst, but the margin miss (23.9% vs 25–30% guidance) appears to be dampening the rally. The market is pricing in caution until management proves margin recovery is real, not just a promise. In other words: growth is believed; profitability is not—yet.
The debate
What to watch next
1 · Q3 FY27 EBITDA margin (Nov–Dec 2026 results)
Will management deliver on the 25–27% recovery target, or stay at 23–24%? This is the single most important metric. If margins improve sequentially (above 24.5%), raw material normalization and price revisions are working. If flat or lower, the miss becomes structural, not temporary.
2 · Rajkot expansion commissioning (Q1 FY28 target, Apr–Jun 2027)
Does the 1,200 MT capacity ramp on time, or slip? On-time execution validates FY28 ₹650–700 Cr guidance credibility. Any delay >1 month raises execution concerns and forces FY28 guidance revision down.
3 · CDMO first commercial revenue (Q4 FY27, Jan–Mar 2027)
Does molecule 1 commercialize on the promised Q4 timeline, and what is the first-quarter contribution? This signals platform readiness and validates management's de-risked FY28 projection (which excludes CDMO pending clarity).
Anlon Healthcare is a genuine growth story: 102% revenue growth, positioned in a structural tailwind (India API outsourcing, China Plus One), and backed by real new capacity coming online. But Q2 raised the stakes. The margin miss (23.9% vs 25–30% guidance) is not excused by one-time items or segment mix—it's operational, and it's credibility-testing. Management's job now is not to grow faster; it's to prove it can grow AND maintain profitability while integrating acquisitions and launching new products.
The number to track from here is Q3 EBITDA margin. If it recovers above 25%, the story is "growth with margin discipline." If it stays at 23–24%, the story shifts to "growth at the cost of profitability," and the valuation case changes. Until management proves it, a Hold is the honest read. The upside is real. So is the risk.